Skip to main content

Table 1 Baseline characteristics of patients

From: Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial

Characteristic

Patients (n = 40)

Age, years, median (range)

56 (27–76)

ECOG PS score, n (%)

 

 0

3 (7.5%)

 1

37 (92.5%)

Number of metastatic sites, median (range)

2 (0–5)

Metastatic sites, n (%)

 

 Lymph nodes

25 (62.5%)

 Lung

9 (22.5%)

 Liver

9 (22.5%)

 Others*

26 (65.0%)

Previous lines of chemotherapy in the advanced setting, median (range)

2 (1–5)

Previous therapy in the advanced setting, n (%)

 

 Taxane

24 (60.0%)

 Anthracycline

32 (80.0%)

 Platinum

20 (50.0%)

 Others#

34 (85.0%)

  1. * Including 13 patients with bone metastasis, one with brain metastasis, two with skin or soft tissue metastasis, 16 with chest wall metastasis, and two with adrenal metastasis
  2. # Including 15 patients given capecitabine, 13 given cyclophosphamide, ten given gemcitabine, nine given vinorelbine, one given fluorouracil, one given eribulin, one given utidelone and one given raltitrexed
  3. ECOG PS: Eastern Cooperative Oncology Group performance status